Celltrion, Inc.
Celltrion, Inc. (KRX: 068270) is trading at ₩179,600.00, about ₹12,962 at today's KRW/INR rate, as of 8 Oct 2026, 2:30 AM ET, down 2.13% today. Celltrion is not currently available to trade on Paasa; this page shows its price, statistics and the Indian tax treatment for information.
Quote
Today's low
₩179,500.00
Today's high
₩182,300.00
52 week low
₩158,500.00
52 week high
₩239,047.62
068270 opened at ₩182,000.00, closed previously at ₩183,500.00, and has traded between ₩158,500.00 and ₩239,047.62 over the past 52 weeks.
About
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Key statistics
Avg. volume
629.45K
Market cap
₩41.19T
P/E Ratio
25.92
Price-to-sales ratio
8.41
Enterprise value
₩42.42T
Free cash flow yield
1.20%
Debt-to-equity ratio
0.22
Return on equity
5.99%
ROIC
4.93%
Beta
0.32
Dividend yield
0.40%
Last dividend
₩714.29
Financial overview
Revenue
₩4.16T
Earnings per share
₩4,466.05
Free cash flow
₩478.24B
Net profit margin
32.19%
Gross margin
60.70%
EBITDA
₩1.45T
Revenue growth
17.01%
Similar securities
This is not an investment recommendation
Celltrion for Indian investors
Celltrion is listed on the Korea Exchange. It is not currently available to trade on Paasa; the figures on this page are for information, and the tax notes below apply to Indian residents who hold it.
Taxes on Celltrion for Indian residents
Trading and limits
- Trading hours
- 9:00 am – 3:30 pm KST
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Celltrion’s current yield is 0.40%.Dividend tax explained
FAQs
Can I buy Celltrion on Paasa?
Celltrion (068270) has been listed on the Korea Exchange since 2005, in the Biotechnology industry. Celltrion is not currently available to trade on Paasa; the figures on this page are for information. Indian residents who hold it through another broker still declare it under the rules below.
How much does one Celltrion share cost in rupees?
One Celltrion share is ₩179,600.00 — about ₹12,962 at a KRW/INR rate of 0.0722 on 8 Oct 2026. Both the Celltrion price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for investing abroad from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability.
How are gains on Celltrion shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the KRW/INR rate on the purchase and the sale date, so the rupee move counts alongside the Celltrion price.
Does Celltrion pay a dividend, and how is it taxed in India?
Yes. Celltrion pays a dividend and the current yield is 0.40%; the last declared dividend was ₩714.29 per share, about ₹51.55. Dividends are taxed at your slab rate in India.
When does KRX trade, in Indian time?
The Korea Exchange trades 5:30 am – 12:00 pm IST in Indian time.
Do I have to declare Celltrion shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. The holding is reported with its cost and its closing value.
Does the rupee rate affect what I make on Celltrion?
Yes. Celltrion is priced in KRW, so your rupee outcome combines the KRW move with the KRW/INR move between the day you remit and the day you convert back.